Oritavancin: Phase III start

The Medicines Co. received SPAs for the planned, double-blind Phase III SOLO-1 and SOLO-2 trials to compare 1,200 mg IV oritavancin vs. IV Vancocin vancomycin. The trials, which are expected to start...